Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives
Plus Therapeutics, through its subsidiary CNSide Diagnostics, secured a reimbursement coverage agreement with Highmark for its CNSide CSF Tumor Cell Enumeration assay, increasing total covered lives from approximately 67 million to 75 million. This expands patient access and supports broader adoption of CNSide in the detection and monitoring of met…